Terrilyn Blackstock, NP
Acute Care · Calhoun, GANPI 1740672542
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,310 of the $3,828 with a category attached, or 86.5%. It is spread thinly across 36 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$506
- AstraZeneca$242
- Merck$236
- Daiichi Sankyo Inc.$204
- E.r. Squibb & Sons, L.L.C.$196
- Seagen Inc.$192
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,31086%
- Education$51714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $506 |
| AstraZeneca(2 entities) | 9 | $242 |
| Merck | 8 | $236 |
| Daiichi Sankyo Inc. | 10 | $204 |
| E.r. Squibb & Sons, L.L.C. | 9 | $196 |
| Seagen Inc. | 8 | $192 |
| Gilead | 5 | $190 |
| Incyte Corporation | 5 | $182 |
| Eisai Inc. | 9 | $160 |
| Exelixis Inc. | 7 | $131 |
| Novartis | 5 | $118 |
| AbbVie | 6 | $110 |
| Regeneron Healthcare Solutions, Inc. | 4 | $109 |
| Sanofi | 5 | $104 |
| Bayer | 4 | $93 |
| Bristol Myers Squibb | 4 | $93 |
| Coherus Oncology, Inc. | 4 | $88 |
| Array Biopharma Inc | 10 | $87 |
| GSK | 3 | $80 |
| Astellas Pharma US Inc | 3 | $74 |
| Jazz Pharmaceuticals Inc. | 3 | $67 |
| Genentech USA, Inc. | 4 | $66 |
| Rigel Pharmaceuticals, Inc. | 3 | $65 |
| Myriad Genetic Laboratories, Inc. | 3 | $59 |
| Beigene USA, Inc. | 3 | $59 |
| Puma Biotechnology, Inc. | 3 | $57 |
| Stemline Therapeutics Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $42 |
| ADC Therapeutics America, Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Foundation Medicine, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Sobi, Inc | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $12 |
How this compares
$3,828 in reported general payments places this provider in the 90th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 17 | $263,257 |
| IbrancePalbociclib | 12 | $188,298 |
| EliquisApixaban | 44 | $27,533 |
| Anastrozole | 130 | $1,865 |
| Exemestane | 23 | $1,109 |
| Prochlorperazine Maleate | 42 | $741 |
| Hydroxyurea | 35 | $686 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 27 | $346 |
| Ondansetron Hcl | 78 | $334 |
| Acyclovir | 30 | $262 |
| Letrozole | 27 | $219 |
| Ondansetron OdtOndansetron | 20 | $181 |
| Hydroxyzine Pamoate | 11 | $134 |
| Gabapentin | 16 | $99 |
| Warfarin Sodium | 15 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $25 | $263,25717 claims |
| PfizerIbrance, Eliquis | $506 | $215,83256 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 679 acute care providers in Georgia.
Other acute care in Calhoun
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
- Ayeshia PowellAtlanta$10K
- Mitzi WilliamsGainesville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.